 |
|
|
Finadyne Paste 10g (pack of 6) |
|
Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic activities. Finadyne Paste is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders in the horse.
|
|
Presentation
Syringes packed with 10g white palatable oral paste. Each syringe contains flunixin meglumine BP (Vet) equivalent to 500 mg flunixin in an inert carrier.
Uses
Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic activities. Finadyne Paste is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders in the horse.
|
|
Dosage and administration
Finadyne Paste is for oral administration only.
The recommended dose of flunixin is 1.1 mg/kg bodyweight once daily for up to five days. The Finadyne Paste syringe is calibrated in 100 kg increments. Turn the syringe dial to the appropriate mark to deliver the correct dose. Each 10 g syringe is sufficient to treat one 1000 lb (455 kg) horse for one day.
The paste is orally administered by inserting the nozzle of the syringe through the interdental space and depositing the required amount of paste on to the back of the tongue.
|
|
Contra-indications, warnings, etc
Not for use in animals intended for human consumption.
Do not exceed the stated dose or the duration of treatment.
Do not administer to pregnant mares. Studies to demonstrate safety in pregnant mares have not been conducted.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is hypersensitivity to the product.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management.
Some NSAIDS may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations which can lead to toxic effects.
Do not administer other NSAIDS concurrently or within 24 hours of each other.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
It is preferable that flunixin is not administered to animals undergoing general anaesthesia until fully recovered.
NSAIDs can cause inhibition of phagocyte and hence in the treatment of inflammation conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.
Do not use in hypovolaemic animals except in the case of endotoxaemia or septic shock.
For animal treatment only.
Keep out of the reach of children.
Pharmaceutical precautions
Do not store above 25°C.
Do not freeze.
Replace cap after use.
Unused syringes should be disposed of in accordance with any guidance from an appropriate waste regulation authority.
|
|
Legal category
POM-V (previously POM).
Packaging Quantities
Syringes of 10 g. Packs of 6×10 g syringes.
Further information
Flunixin meglumine is also presented as Finadyne Solution and Finadyne Granules which may be used as an alternative to Finadyne Paste. A suggested dosage regime is an initial injection of Finadyne Solution followed by Finadyne Paste or Finadyne Granules on subsequent days.
Studies in horses have shown onset of activity occurs two hours after oral administration. Peak response occurs between 12 and 16 hours and the duration of activity is 24 to 36 hours.
Veterinary Surgeons administering NSAIDs to racehorses should refer to Section 4.4 of the RCVS Guide to Professional Conduct. Section 4.4.7 states, ``If a veterinarian recommends the discontinuance of any substance . . . not less than eight days before racing (even though such a period may be longer than is necessary in many instances) he should be able to feel sure that he has catered for all but the most exceptional cases''.
Marketing authorisation number
Vm 0201/4012.
|
|
|
